Skip to content

The influence of esketamine analgesia on emotional distress of palliative inpatients. A retrospective analysis.

The influence of esketamine analgesia on emotional distress of palliative inpatients. A retrospective analysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00013208
Enrollment
8
Registered
2017-10-27
Start date
2017-10-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emotional distress caused by symptoms of depression and anxiety Pain

Interventions

Group 1: Retrospective analysis of routinely collected inpatient data of a one-year time interval (01.04.2016-31.03.2017). The analysis includes the following general variables: age, gender, diagnosi

Sponsors

Interdisziplinäres Zentrum für Palliativmedizin der Universitätsklinik Düsseldorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All inpatients (age =18 years) which are treated from 01.04.2016 to 31.03.2017 in the Interdisciplinary Center for Palliativ Medicine and for which the primary and secondary outcome variable exists before and after esketamine administration are included in to the analysis.

Exclusion criteria

Exclusion criteria: Age < 18 years

Design outcomes

Primary

MeasureTime frame
Primary outcome: State-Trait-Anxiety-Depression-Inventory (STADI) global score (which operationalizes emotional distress through depression and anxiety). In the Interdisciplinary Center for Palliative Medicine the STADI is administered regulary in a time interval of 1 to 5 days. In the analysis we will include the STADI global score before and after the esketamin application.

Secondary

MeasureTime frame
Numerical rating scale of pain and Scale to register anxiety and restlessness. In the Interdisciplinary Center for Palliative Medicine these questionnaires are evaluated several times a day. The timepoints of interest are the day before, while and after esketamine application. In addition, the day of STADI evaluation before and after esketamine application. In this analysis we want to calculate the median and dispersion of these variables on the mentioned timepoints, as well as for the whole length of stay.

Countries

Germany

Contacts

Public ContactMartin Neukirchen

Interdisziplinäres Zentrum für Palliativmedizin der Universitätsklinik Düsseldorf

martin.neukirchen@med.uni-duesseldorf.de(0211) 81-08700

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026